FDA’s Regulation of Veterinary Regenerative Medicine - Webinar By ComplianceOnline

This webinar will provide an introduction to FDA’s regulation of veterinary regenerative medicine and highlight the regulatory requirements that a biotech company needs to satisfy to commercialize a stem cell or other complex biotech product for animal use in the U.S.

Why Should You Attend:

The rapid development of cell-based and related biological therapies for use in veterinary medicine has provided exciting new options for the safe and effective treatment of common veterinary diseases and conditions such as osteoarthritis, tendon strain injuries, suspensory desmitis, congestive heart failure and other commonly diagnosed diseases and injuries.

Areas Covered in the Seminar:

• Who regulates veterinary cellular and tissue products; and biotherapeutic products intended for commercialization.
• FDA's regulation of veterinary regenerative medicine including stem cells and other biotherapeutics.
• FDA's currently regulation of human cellular and tissue products; and how those same regulatory policies may be applied to veterinary products.
• Discussion of the new animal drug approval process.
• The potential for a drug / non-drug distinction to be made between products based on the amount of processing applied to the product.